Compare Ascendis Pharma A/S (ASND) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs NextEra Energy, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while NextEra Energy, Inc. trades at $87.84 (market cap $183.45B). The key difference: NextEra Energy, Inc. is far larger — about 10.3× Ascendis Pharma A/S's market cap, and NextEra Energy, Inc. pays a 2.83% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NEE | |
|---|---|---|
Market Cap | $17.74B | $183.45B |
Sector | Health | Utilities |
52-Week High | $277.18 | $97.88 |
52-Week Low | $163.32 | $69.77 |
Enterprise Value | $18.11B | $285.85B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
NextEra Energy (NEE) trades at $87.96, up 0.99% on the day, with a bearish technical signal despite positive earnings momentum. The company reported strong Q1 2026 EPS of $1.09, beating expectations, and maintains robust profitability with a 29.37% net income margin. Recent news highlights the Dominion deal as a major catalyst, while analyst consensus remains strongly bullish with a $104.43 price target representing 19% upside potential.
NEE presents a compelling long-term investment opportunity driven by clean energy demand and strategic partnerships, though near-term technical weakness and rising debt levels warrant caution. The stock's current valuation at 22.32x P/E appears reasonable given growth prospects, but regulatory uncertainty from recent acquisitions and capital-intensive operations pose execution risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
